OncoHost, a technology company focused on transforming the approach to precision oncology through proteomics and AI, announced on Thursday that it has been honoured as a Gold Winner in the 2025 Merit Awards for Healthcare, with recognition as Technology Solution of the Year.
The Merit Awards for Healthcare are designed to recognise companies delivering breakthrough technologies that meaningfully advance patient care.
OncoHost received top honours for its PROphet platform, an AI-powered, plasma-proteomics solution that predicts patient response to cancer therapy using a single pre-treatment blood sample.
Ofer Sharon, MD, OncoHost CEO, said: "This recognition from the Merit Awards highlights the meaningful clinical value the PROphet platform brings to cancer care. Our goal is to provide oncologists with clear, actionable insights that support more confident and informed treatment decisions from day one. We appreciate this acknowledgment of our team's ongoing work to advance precision oncology."
Innovent Biologics reports first participant dosed in Phase 1 trial of IBI3011
D3 Bio completes USD108m Series B financing round
Cereno Scientific's Phase IIb trial of CS1 in PAH approved by US FDA
ALR Technologies announces GluCurve Pet CGM relaunch in Canada
Champions Oncology expands bioanalytical services with new technology and leadership
Poolbeg Pharma trial to feature in major CRS research programme
PureTech clears key FDA milestone for Phase 3 development of deupirfenidone
Natera acquires Foresight Diagnostics to expand MRD capabilities